

제 17 장

골다공증의 기타 치료

1. Adler RA, El-Haji Fuleihan G, Bauer DC, Camacho PM, Clarke BL, Clines GA, et al. Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American society for bone and mineral research. *J Bone Miner Res* 2016;31:16-35.
2. Lobo RA, Pinkerton JV, Gass ML, Dorin MH, Ronkin S, Pickar JH, et al. Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile. *Fertil Steril* 2009;92:1025-38.
3. Pinderton JV, Harvey JA, Pan K, Thompson JR, Ryan KA, Chines AA, et al. Breast effects of bazedoxifene-conjugated estrogen: a randomized controlled trial. *Obstet Gynecol* 2013;121:959-68.
4. Pinkerton JV, Harvey JA, Lindsay R, Pan K, Chines AA, Mirkin S, et al; SMART-5 investigators. Effects of bazedoxifene/conjugated estrogens on the endometrium and bone: a randomized trial. *J Clin Endocrinol Metab* 2014;99:E189-98.
5. Kim KM, Lee SY, Rhee Y. Influence of dosing interval and administration on the bone metabolism, skeletal effects, and clinical efficacy of parathyroid hormone in treating osteoporosis: a narrative review. *JBMR Plus* 2017;6:36-45.
6. McClung MR. Romosozumab for the treatment of osteoporosis. *Osteoporos Sarcopenia* 2018;4:11-5.
7. Cummings SR, Martin JS, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C; the FREEDOM Trial. Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis. *N Engl J Med*. 2009;361:756-65
8. Miller PD, Bolognese MA, Lewiecki EM, McClung MR, Ding B, Austin M, Liu Y, San Martin J, Amg Bone Loss Study Group. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. *Bone*. 2008;43:222-9.
9. Papapoulos S, Lippuner K, Roux C et al The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study *Osteopo Int* 2014

10. Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, O’Ryan F; American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. *J Oral Maxillofac Surg.* 2014 Oct;72(10):1938-56
11. Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR, Czerwiński E, Fahrleitner-Pammer A, Kendler DL, Lippuner K, Reginster JY, Roux C, Malouf J, Bradley MN, Daizadeh NS, Wang A, Dakin P, Pannacciulli N, Dempster DW, Papapoulos S. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. *Lancet Diabetes Endocrinol.* 2017 Jul;5(7):513-23.
12. Miller PD, Wagman RB, Peacock M, Lewiecki EM, Bolognese MA, Weinstein RL, Ding B, San Martin J, McClung MR. Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial. *J Clin Endocrinol Metab.* 2011 Feb;96(2):394-402
13. Tsourdi E, Langdahl B, Cohen-Solal M, Aubry-Rozier B, Eriksen EF, Gueñabens N, Obermayer-Pietsch B, Ralston SH, Eastell R, Zillikens MC. Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS. *Bone.* 2017 Dec;105:11-7
14. Anastasilakis AD, Polyzos SA, Makras P, Aubry-Rozier B, Kaouri S, Lamy O. Clinical Features of 24 Patients With Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: Systematic Review and Additional Cases. *Bone Miner Res.* 2017 Jun;32(6):1291-6
15. Anagnostis P, Paschou SA, Mintziiori G, Ceausu I, Depypere H, Lambrinouadaki I, Mueck A, Pérez-López FR, Rees M, Senturk LM, Simoncini T, Stevenson JC, Stute P, Trémollières FA, Goulis DG. Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement. *aturitas.* 2017 Jul;101:23-30
16. Iranikhah M, Deas C, Murphy P, Freeman MK. Effects of Denosumab After Treatment Discontinuation : A Review of the Literature. *Consult Pharm.* 2018 Mar 1;33(3):142-151
17. Harrison’s Principles of Internal Medicine 19e, 2016, CHAPTER 425. Osteoporosis, GLUCOCORTICOID-INDUCED OSTEOPOROSIS
18. Goldman’s Cecil Medicine , 25e, 2016, Chapter 243. Osteoporosis, Glucocorticoid-Induced and Male Osteoporosis
19. Conn’s Current Therapy , 2012 > Section1. Symptomatic Care Pending Diagnosis, Table2. Examples of Corticosteroids
20. CURRENT Diagnosis & Treatment: Physical Medicine & Rehabilitation, 2015, 20: Pediatric Rehabilitation, COMMON PEDIATRIC NEUROMUSCULAR DISEASES,

A. Pharmacotherapy

21. Clinical Neurology, 10e ,2018, Chapter 9: Motor Disorders
22. 대한골다공증학회, 골절을 동반한 골다공증의 진료지침, 2017
23. 대한골대사학회, 골다공증 진단 및 진료지침, 2015
24. AACE (AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY) 2016
25. NOGG 2017 (National Osteoporosis Guideline Group), Section 8: Glucocorticoid-induced osteoporosis
26. NOF 2014 (National Osteoporosis Foundation), 4. APPROACH TO THE DIAGNOSIS AND MANAGEMENT OF OSTEOPOROSIS
27. NICE, Osteoporosis (QS149) April 2017, Use of systemic glucocorticoids , Osteoporosis: assessing the risk of fragility fracture (CG146) February 2017
28. Saag KG, et al, Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med. 1998 Jul 30;339(5):292-9.
29. Wallach S, et al, Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int. 2000 Oct;67(4):277-85.
30. Reid DM, et al, Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2009 Apr 11;373(9671):1253-63. doi: 10.1016/S0140-6736(09)60250-6.
31. Buckley L, et al, 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Care Res (Hoboken). 2017 Aug;69(8):1095-1110. doi: 10.1002/acr.23279. Epub 2017 Jun 6.
32. Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA 2013;310:1353-1368.
33. Beral V; Million Women Study Collaborators, Bull D, Green J, Reeves G. Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet 2007;369:1703-1710.
34. Danforth KN, Tworoger SS, Hecht JL, Rosner BA, Colditz GA, Hankinson SE. A prospective study of postmenopausal hormone use and ovarian cancer risk. Br J Cancer 2007;96:151-156.
35. Trabert B, Wentzensen N, Yang HP, et al. Ovarian cancer and menopausal hormone therapy in the NIH-AARP diet and health study. Br J Cancer 2012;107:1181-1187.
36. Gabriel CA, Tigges-Cardwell J, Stopfer J, Erlichman J, Nathanson K, Domchek SM.

Use of total abdominal hysterectomy and hormone replacement therapy in BRCA1 and BRCA2 mutation carriers undergoing riskreducing salpingo-oophorectomy. *Fam Cancer* 2009;8:23-28.

37. Li D, Ding CY, Qiu LH. Postoperative hormone replacement therapy for epithelial ovarian cancer patients: a systematic review and metaanalysis. *Gynecol Oncol* 2015;139:355-362.
38. Marjoribanks J, Farquhar C, Roberts H, Lethaby A, Lee J. Long-term hormone therapy for perimenopausal and postmenopausal women. *Cochrane Database Syst Rev* 2017;1:CD004143.